Literature DB >> 10923770

Characteristics of deaths in a department of oncohaematology within a general hospital. A study of 81 cases.

F Bauduer1, C Capdupuy, M Renoux.   

Abstract

We aimed to perform a prospective analysis of the main characteristics of deaths occurring in the oncohaematology department of a general hospital. From November 1995 to February 1997, a total of 81 patients died in our unit, 50 of whom (61.7%) were male. Their mean age was 67.8 (range 19-96) years. Underlying diseases were: multiple myeloma (9 cases), acute myeloid leukaemia (22), lymphoma (14), chronic lymphocytic leukaemia (6), acute lymphoblastic leukaemia (4), myelodysplastic syndromes (3), solid tumours (11), and other (12). The previous disease duration ranged from 5 days to 276 months (mean 31.9 months). The duration of the last hospital stay varied between 0 (death on arrival or on way to hospital) and 40 days (mean 9.3 days). Two patients died in the emergency unit just before entering our department (1 suicide). Only 15 patients had been admitted for the first time. In 70% of these cases death appeared predictable, as the consequence of refractory or end-stage disease. In these cases, all the "do not resuscitate" orders were in place at least 48 h before death. About half the patients died without any relative present. The frequencies of the clinical complaints evaluated were the following: pain necessitating opiates 27%; infection- or disease-related fever 40%; dyspnoea 44%; haemorrhage 20%; CNS disturbances 25%. The percentages of use of therapy tools chosen as indicators were: benzodiazepines 80%; chemotherapy 46%; anti-infectious agents 47%; transfusions 42%; major analgesics 27%; and steroids 40%. The circumstances and quality of patient deaths must be regularly evaluated so that palliative care in the final stages of life can be improved.

Entities:  

Mesh:

Year:  2000        PMID: 10923770     DOI: 10.1007/s005209900087

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  7 in total

1.  Dying of hematologic patients--treatment characteristics in a German University Hospital.

Authors:  Patrick Brück; Malgorzata Pierzchlewska; Marta Kaluzna-Oleksy; Maria Elizabeth Ramos Lopez; Mathias Rummel; Dieter Hoelzer; Angelika Böhme
Journal:  Support Care Cancer       Date:  2012-03-13       Impact factor: 3.603

2.  Hospice admissions for cancer in the final days of life: independent predictors and implications for quality measures.

Authors:  Nina R O'Connor; Rong Hu; Pamela S Harris; Kevin Ache; David J Casarett
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

3.  Factors associated with place of death of cancer patients in the Mexico City Metropolitan area.

Authors:  Marylou Cárdenas-Turanzas; María Teresa Carrillo; Horacio Tovalín-Ahumada; Linda Elting
Journal:  Support Care Cancer       Date:  2006-10-05       Impact factor: 3.603

4.  Clinical, sociodemographic, and local system factors associated with a hospital death among cancer patients.

Authors:  Marylou Cárdenas-Turanzas; Richard M Grimes; Eduardo Bruera; Beth Quill; Guillermo Tortolero-Luna
Journal:  Support Care Cancer       Date:  2005-04-21       Impact factor: 3.603

5.  Symptom burden and supportive care in patients with acute leukemia.

Authors:  Camilla Zimmermann; Dora Yuen; Ashley Mischitelle; Mark D Minden; Joseph M Brandwein; Aaron Schimmer; Lucia Gagliese; Christopher Lo; Anne Rydall; Gary Rodin
Journal:  Leuk Res       Date:  2013-03-11       Impact factor: 3.156

6.  End-of-life characteristics and palliative care provision for elderly patients suffering from acute myeloid leukemia.

Authors:  Hon-Wai Benjamin Cheng; Cho-Wing Li; Kwok-Ying Chan; Ho-Yan Au; Pan-Fong Chan; Yim-Ching Sin; Yan Szeto; Mau-Kwong Sham
Journal:  Support Care Cancer       Date:  2014-07-05       Impact factor: 3.603

Review 7.  Thermo-Sensitive TRP Channels: Novel Targets for Treating Chemotherapy-Induced Peripheral Pain.

Authors:  Mustafa Nazıroğlu; Nady Braidy
Journal:  Front Physiol       Date:  2017-12-13       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.